Swiss National Bank boosted its holdings in shares of Axovant Sciences Ltd (NYSE:AXON) by 17.5% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 53,600 shares of the biotechnology company’s stock after purchasing an additional 8,000 shares during the quarter. Swiss National Bank’s holdings in Axovant Sciences were worth $1,243,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of AXON. Point72 Asset Management L.P. increased its holdings in Axovant Sciences by 1,718.3% during the 1st quarter. Point72 Asset Management L.P. now owns 209,100 shares of the biotechnology company’s stock worth $3,124,000 after purchasing an additional 197,600 shares during the last quarter. Prudential Financial Inc. increased its holdings in Axovant Sciences by 700.9% during the 2nd quarter. Prudential Financial Inc. now owns 80,170 shares of the biotechnology company’s stock worth $1,859,000 after purchasing an additional 70,160 shares during the last quarter. Federated Investors Inc. PA purchased a new stake in Axovant Sciences during the 2nd quarter worth approximately $1,408,000. C WorldWide Group Holding A S increased its holdings in Axovant Sciences by 20.0% during the 2nd quarter. C WorldWide Group Holding A S now owns 131,500 shares of the biotechnology company’s stock worth $3,049,000 after purchasing an additional 21,900 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its holdings in Axovant Sciences by 27.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 102,664 shares of the biotechnology company’s stock worth $2,380,000 after purchasing an additional 21,801 shares during the last quarter.

Several research analysts have recently commented on the company. Jefferies Group LLC set a $40.00 target price on Axovant Sciences and gave the stock a “buy” rating in a research report on Friday, August 25th. Evercore ISI assumed coverage on Axovant Sciences in a research report on Friday, September 8th. They issued an “outperform” rating and a $30.00 target price for the company. Chardan Capital reiterated a “sell” rating and issued a $3.00 target price on shares of Axovant Sciences in a research report on Saturday, September 23rd. Zacks Investment Research upgraded Axovant Sciences from a “hold” rating to a “strong-buy” rating and set a $8.00 target price for the company in a research report on Monday, October 9th. Finally, Oppenheimer Holdings, Inc. reiterated a “buy” rating and issued a $30.00 target price on shares of Axovant Sciences in a research report on Monday, September 25th. Three analysts have rated the stock with a sell rating, five have issued a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $14.13.

Axovant Sciences Ltd (AXON) opened at 6.18 on Friday. The company’s 50-day moving average price is $13.93 and its 200-day moving average price is $13.93. Axovant Sciences Ltd has a 52-week low of $6.08 and a 52-week high of $27.98. The firm’s market cap is $664.50 million.

Axovant Sciences (NYSE:AXON) last issued its earnings results on Monday, August 7th. The biotechnology company reported ($0.65) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.53) by ($0.12). Analysts predict that Axovant Sciences Ltd will post ($2.02) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Swiss National Bank Has $1.24 Million Holdings in Axovant Sciences Ltd (AXON)” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/10/14/swiss-national-bank-has-1-24-million-holdings-in-axovant-sciences-ltd-axon.html.

Axovant Sciences Company Profile

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Institutional Ownership by Quarter for Axovant Sciences (NYSE:AXON)

Receive News & Stock Ratings for Axovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd and related stocks with our FREE daily email newsletter.